Investing.com UK - Financial Markets Worldwide
Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Medtronic Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Published 20/02/2024, 07:23
© Reuters. Medtronic Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
MDT
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Medtronic plc (NYSE: MDT) is expected to release earnings results for its third quarter of fiscal year 2024, before the opening bell on Feb. 20, 2024.

Analysts expect the Dublin, Ireland-based company to report quarterly earnings at $1.26 per share, down from year-ago earnings of $1.3 per share. Medtronic is projected to report quarterly revenue of $7.95 billion, according to data from Benzinga Pro.

The company recently announced CE (Conformité Européenne) Mark approval for the MiniMed 780G system with Simplera Sync, a disposable, all-in-one continuous glucose monitor (CGM) which does not require a fingerstick or overtape.

Additionally, Medtronic announced that it received FDA approval of its Percept RC Deep Brain Stimulation (DBS) system.

Medtronic shares fell 0.4% to close at $84.42 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

  • Truist Securities analyst Richard Newitter maintained a Hold rating and boosted the price target from $84 to $87 on Dec. 22, 2023. This analyst has an accuracy rate of 73%.
  • Oppenheimer analyst Steven Lichtman reiterated a Perform rating with a price target of $89 on Aug. 23, 2023. This analyst has an accuracy rate of 72%.
  • UBS analyst Matthew Taylor maintained a Sell rating and increased the price target from $79 to $82 on Aug. 23, 2023. This analyst has an accuracy rate of 68%.
  • Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and raised the price target from $100 to $102 on Aug. 23, 2023. This analyst has an accuracy rate of 73%.
  • Stifel analyst Rick Wise maintained a Buy rating and increased the price target from $92 to $95 on Aug. 23, 2023. This analyst has an accuracy rate of 76%.

Read This Next: Top 5 Industrials Stocks That May Collapse This Quarter

Latest Ratings for MDT

DateFirmActionFromTo
Feb 2022Credit SuisseMaintainsOutperform
Feb 2022NeedhamMaintainsBuy
Feb 2022Raymond JamesMaintainsOutperform
View More Analyst Ratings for MDT

View the Latest Analyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.